Bär & Karrer Partner Daniel Hochstrasser Nominated for the Board of Directors of Novartis

Bär & Karrer is proud to announce that Daniel Hochstrasser has been nominated for the Board of Directors of Novartis, a global healthcare company based in Switzerland, to be elected at the Annual General Assembly on 4 March 2022. As planned for some time, Daniel Hochstrasser will retire from the partnership of Bär & Karrer at the end of 2022 after 29 years at the firm, thereof ten years as senior partner.

Susanne Schreiber, senior partner of Bär & Karrer, commented: "I warmly congratulate Daniel Hochstrasser on his nomination and am convinced that he will be a great choice for Novartis' Board of Directors."